Full Description
This open access book is written by world-renowned experts on radiomolecular precision oncology to celebrate the work, life, principles and ideology of Richard P Baum.
It includes commentaries, reviews and some thought provoking novel ideas on radionuclide precision oncology, covering topics such as various aspects of theranostics and molecular radiotherapy like radiolabeled peptides, radiolabeled antibodies, dosimetry, and quality control as well as the diagnosis and treatment of specific tumor types. Featuring contributions by biologists, physicists, chemists, mathematicians, geneticists, and physicians from a range of specialties, this Festschrift is highly interdisciplinary and will be a valuable resource for future precision oncologists.
Contents
1. The Rise of A Theranostic Empire: Good Governance and Precision Oncology.- 2. 18 FDG PET CT assessing Inmunotherapy response.- 3. Radionuclide Therapy in Brain Tumours.- 4. From Concept to Clinic and Comercialisation - Cowboys Wanted.- 5. From Radiochemistry of the Lanthanides to 225Ac and the interference with Richard Baum .- 6. How do you feel about dosimetry?" The Gretchenfrage of Radionuclide Therapy.- 7. The LuGenIum Triptych Ode to a Theranostic Transcriptome.- 8. A tree can be recognized by its fruit.- 9. IAEA Strategy for Enhancing the Sustainability of Nuclear Medicine in Low- and Middle- Income Countries.- 10. Combining surgery with peptide receptor radionuclide therapy - a step forward in treatment of advanced neuroendocrine tumours.- 11. Modern diagnostic and therapeutic approaches in thyroid diseases - Theranostics and the changing role of radioactive isotopes -.- 12. Cardiotoxicity of targeted therapies: Imaging of Heart Does Matter.- 13. Following the co-evolution of Innovation and demand in the field of precision oncology.- 14. Fighting for PET in German oncological guidelines and for its reimbursement by Statutory Health Insurances.- 15. Precision Oncology with PSMA-targeted Alpha Particle Therapy of mCRPC.- 16. From Radioimmunodetection to Radiomolecular Precision Oncology via Radionanotargeting by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles.- 17. Nuclear medicine and surgery a new productive new marriage.- 18. 'PSMA Radioligand Therapy - A Revolution in the Precision Oncology of Prostate Cancer'.- 19. The Role of Individuals for Innovation: The Nuclear Medicine Biotope.- 20. Working at ISOTOPENTHERAPIESTATION D3- a daily challenge or adventure never stops.- 21. Combining targeted radiation therapies in modern clinical oncological practice.- 22. Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening & Clinical Translation.- 23. Terbium "Sisters": More than just a "Swiss Army Knife".- 24. High-Performance Radiopharmacy - The Base for Precision Oncology.- 25. Analyzing the science footprint of Richard P. Baum.- 26. Ac-225 PSMA in metastatic prostate cancer without previous chemotherapy.- 27. 'Sola dosis facit venenum: Dosimetrie in Precision Oncology with Radiolabelled Probe'.- 28. theranostic pair 203Pb and 212Pb for image-guided alpha/beta particle therapy for cancer..- 29. Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors.- 30. A (188)Re-juvenatiNG JOURNEY WITH HERCULES .- 31. CXCR4 Theranostic Experience from India.- 32. Can VPAC Targeted Cu-67-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest.- 33. REAL-WORLD EVIDENCE: CLINICAL OUTCOMES IN PRECISION RADIONUCLIDE ONCOLOGY. The WARMTH NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer..- 34. Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in primary neuroendocrine tumors, metastases, and normal liver tissue - isthere a significant difference?.- 35. Theranostics with somatostatin receptor antagonists..- 36. Molecular in-vitro & in-vivo diagnostics as the impartible basis of multimodal therapy approaches in precision oncology .- 37. Molecular imaging platform and radio-pharmaceutical transnational research on Peking University Cancer Hospital.- 38. Dose it possible to targeting HER2 using Affibody receptor radionuclide therapy.
